Pharmaseal enters the market with new CTMS platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/pinkypills)
(Image: Getty/pinkypills)

Related tags: Clinical trial, Clinical trial management, Clinical data, Clinical data management, Biopharmaceutical, cloud based software

Pharmaseal is entering the clinical trial management and governance solutions market with the launch of Engility – the company’s new CTMS platform.

Engility is the first product released from the company’s Engility B2B platform. The clinical trial management system (CTMS) was designed to support multiple languages, and the company intends to add other eClinical management applications to the platform after the CTMS has been commercialized, Pharmaseal CEO Daljit Cheema told us.

The CTMS has an interface and cloud architecture for the use of biopharmaceutical companies to leverage enterprise technology for its organization model.

 “CTMS provides a central system where all clinical trials are recorded and managed and becomes a corporate knowledge base of their clinical trials,” ​Cheema added.

”It allows important enterprise information to be stored in a single place and then shared with many other business areas and systems reducing the duplication of information.”

Cheema said the CTMS also provides senior management visibility into the overall progress of their clinical trials and enables decisions to be made quickly.

The CTMS platform was built using a modern shared cloud-based architecture. This structure works to also optimize the cost of software validation so that new innovations can be introduced easily for the benefit of customers, according to the company.

The company also implemented an agile flow-based engineering model that uses a continuous validation framework developed by Pharmaseal.

“This utilises extensive test automation which means every requirement is traceable through to all the associated deliverables that are produced during the engineering process. We are also able to generate a critical functionality document based on a behavioral specification that documents both a functional requirement and the associated functional test,”​ Cheema said. 

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars